We propose ABCB1 as an effective molecular target for carboplatin-resistant ovarian cancers harboring p53null mutations, which we uncovered could be used to increase the efficacy of conventional anti-cancer therapies, to develop more efficient combinatorial therapeutic interventions directed toward overcoming the chemoresistance and improving the survival rates in patients with ovarian cancer. This evidence concerns the gene ABCB1 and ovarian cancer.